&Aminolevulinate dehydratase (ALAD) is the second enzyme in the heme biosynthesis pathway. ALAD is a zinc metalloenzyme, and its inhibition by lead substitution for zinc is one of the most sensitive indicators of blood-lead accumulation, a measure of recent lead exposure. Stoichiometry calculations indicate that a significant portion of blood lead is stored in ALAD. Human ALAD exhibits a charge polymorphism, with about 20% of Caucasians expressing the rarer ALAD2 allele. Human ALAD1 and ALAD2 cDNAs and the 16-kb ALAD gene have been cloned and sequenced. A simple polymerase chain reaction test has been established and validated for determining ALAD genotypes. Two population studies have indicated that lead-exposed individuals with the ALAD allele have blood-lead levels about 10 pg/dl greater than similarly exposed individuals carrying only the ALAD1 allele. Ongoing work is directed toward determining the biochemistry underlying the allele-specific accumulation of blood lead, and toward determining the contribution of human ALAD genotype to lead accumulation in other tissues in transgenic mouse models and to final lead deposition in bone in both mouse and man. -Environ Health Perspect 102(Suppl 3): 215-219 (1994) 
Introduction
Exposure to environmental lead may affect numerous organ systems, including the renal, reticuloendothelial, reproductive, and nervous systems. Of particular importance, exposure to low levels of lead in utero or in early childhood may lead to irreversible central nervous system damage (1) (2) (3) (4) (5) (6) (7) (8) .
Although the reduced use of leaded gasoline, widespread detection of lead-based paint poisoning of children, and control of lead exposure in the workplace have combined to substantially reduce the incidence of acute lead poisoning in the United States, exposure to low doses of lead is still quite common. The Second National Health and Nutrition Examination Survey (NHANES-II) found that 1.5 million preschool children had blood lead levels of 25 pg/dl and above, indicating significant lead absorption.
The homooctameric zinc metalloenzyme, 6 -aminolevulinate dehydratase (porphobilinogen synthase, ALAD, EC 4.2.1.24), is the second enzyme in the heme biosynthetic pathway. ALAD is expressed in all tissues, but occurs at elevated levels in liver, which has the added burden of cytochrome P450 synthesis, and in the highest levels in erythrocytes and their precursors. ALAD is stoichiometrically inhibited by lead (9) (10) (11) , with lead replacing zinc. Erythrocyte ALAD inhibition has been used as a routine leadpoisoning test in many clinical chemistry laboratories.
Lead inactivation of ALAD has been implicated in the pathogenesis of lead poisoning (12, 13) . The substrate of ALAD, 6-aminolevulinate (ALA), which accumulates in lead poisoning, has been shown to be capable of acting as a neuropathogenic agent (11, (14) (15) (16) (17) (18) (19) . In fact, the clinical features of acute lead poisoning closely resemble those of the acute attacks in acute intermittent porphyria (AIP), during which ALA accumulates. AIP is a dominant porphyria due to half-normal levels of the third enzyme in the heme biosynthesis pathway. Furthermore, affected individuals with the recessive ALAD-deficient porphyria manifest chronic neurologic manifestations (20) (21) (22) . Finally, asymptomatic heterozygotes for the latter porphyria develop acute lead poisoning when exposed to low levels of lead (23, 24) .
Three distinct charge isozymes, designated ALAD 1-1, 1-2, and 2-2 (25, 26) , result from the expression of two common 1 2 alleles, designated ALAD and ALAD with gene frequencies of 0.9 and 0.1, respectively, in several Caucasian populations (25) (26) (27) (28) . The existence of this frequent polymorphism in a gene whose product was implicated in the pathogenesis of lead toxicity suggested the potential for a genetically determined differential susceptibility. We determined the ALAD isozyme types of 1278 blood samples from children subjected to low-level environmental lead exposure in New York City (28, 29) . The blood lead level, measured by the New York City Lead Screening Program, and the ALAD isozyme phenotype were determined in a double-blind fashion. Bloodlead levels and isozyme phenotypes were also determined for a population of 202 lead workers in a factory in Germany (30 also the chronic measures of dentine or bone lead. The results reported above are consistent with the testable hypothesis that the ALAD2 subunit binds lead more effectively, with similarly exposed ALAD2 heterozygotes and homozygotes having higher blood lead concentrations and possibly higher lead body burden than ALAD1 homozygotes. We have developed an expression system that allows production of large quantities of human ALAD 1-1 and ALAD 2-2 in Escherichia coli (Kaya AH and Desnick RJ, unpublished results). The present status of biochemical studies of the contribution of these ALAD isozymes to lead poisoning is detailed in the Results and Discussion section. Of particular interest will be the competition between lead and zinc for binding to the isozymes.
The human genomic sequence containing AIAD has been determined (15, 913 bp, accession number X64467) in both orientations (33 (34) or on production of transgenic mice carrying either ALAD1 or ALAD2 human minigenes with promoters for either exon IA or lB. Of special interest will be the acute measure of erythrocyte lead, the chronic measure of bone lead, and the pathophysiologically important distribution of lead into brain.
Materials and Methods

Human Studies
Populations. To date only two populations have been studied (double-blind) for blood lead and ALAD phenotype (29 (33) . The analysis of the genome structure of human ALAD, necessary for constructing transgenic mice expressing human ALAD, is illustrated in Figure 1 .
Results and Discussion
Humanl Studies
The results of the two completed studies demonstrating a relationship between blood lead levels and ALAD phenotype (29) (27) . The results were not changed in a reanalysis excluding these children. Because of the low frequency of ALAD2 even in Caucasian populations, the populations of lead-exposed individuals on whom integrated measures are performed must be quite large to lead to highly informative data; not even the largest of the populations identified to date is ideal. Once again, we invite collaborative arrangements. ALAD 1-1 and ALAD 2-2 Biochemistry The argument that erythrocyte ALAD binds a substantial fraction of the blood lead is outlined in Table 2 . A unit (U) of ALAD is defined as the quantity of enzyme producing 1 nmole porphobilinogen (PBG) per hour at 370 C. The calculation includes the ALAD activity in human erythrocyte lysate (38) of approximately 4.7 U/mg protein (mostly hemoglobin) and the turnover number of 11 mole/min/mole ALAD subunit (36) . The conclusion is that at least 10 pg/dl lead is bound to ALAD at 25 jig/dl total blood lead. This minimum estimate is based on ALAD enzymatic activity, which decreases throughout the 120-day life-span of erythrocytes. Additional lead could be bound to (33) . Thus we are investigating these mice to establish the effect of ALAD concentration, especially in serum, on the pharmacokinetics of lead tissue distribution. These studies will be the basis for measurement and analysis in the more important animal model system based on expression of human ALAD alleles in transgenic mice. As described in Materials and Methods, our efforts to date have been directed toward analysis of the human ALAD gene with particular emphasis on the promoter regions. The structure of the human ALAD gene is shown in Figure 1 . Expression analysis of the two promoters reveals that in both cases a DNA sequence of less than 400 base pairs produces as much product as longer constructs and exhibits tissue specificity. Thus, four minigenes are being constructed containing either exons 2 tol2 of ALAD1 or ALAD and either exon 1A or exon lB with their corresponding promoters. We propose to construct transgenic mice expressing similar numbers of copies of either the human ALAD or ALAD2
allele. The analysis of lead-exposed animals will be directed toward the study of the acute measure of erythrocyte lead, the chronic measure of bone lead, and the pathophysiologically important distribution of lead into brain. In summary, we are taking advantage of the tools of molecular biology to study the ecogenetics of lead poisoning. Our integrated tripartite approach is to study ALAD allele frequency in lead-exposed individuals by PCR, ALAD isozyme biochemistry with recombinant proteins, and the effect of human ALAD alleles on lead pharmacokinetics in transgenic mice.
